CERTAINTY Overview
- Website
- www.certainty-virtualtwin.eu
- Industry
- Biotechnology Research
- Employees
- 126
- Founded
- 2023
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
About CERTAINTY
CERTAINTY (A Cellular Immunotherapy Virtual Twin for Personalised Cancer Treatment) is a four-year research project funded by the European Union under Grant Agreement number 101136379. It brings together 17 partners from across Europe, coordinated by Fraunhofer (Germany), with a shared mission to personalise cancer care. The project is focused on developing a virtual twin for patients undergoing CAR T cell therapy, a pioneering form of cancer treatment. By creating a computational model that mirrors individual patients, CERTAINTY aims to support doctors and patients with insights that may guide treatment decisions and improve outcomes. Our goal is to contribute to a more informed, data-driven approach to cancer therapy, enhancing the effectiveness and safety of personalised treatments through cutting-edge digital tools.
Compare Similar Companies to CERTAINTY
Fraunhofer IZI
Biotechnology Research
HealthTree Foundation
Research Services
DaiSyBio
Research Services
CRIDS/NaDI
Research Services
SIMCor
Hospitals And Health Care
EDITH-CSA
Hospitals And Health Care
CancerDataNet GmbH (acquired by TriNetX)
Biotechnology Research
DGKL Kongress 2024
Civic And Social Organizations
Leistungszentrum Einzelzelltechnologien LZ-EZT
Research Services
Teach4MD
Medical Device